|
1
|
Yáñez-Muñoz RJ, Balaggan KS, MacNeil A,
Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN,
Barker SE, et al: Effective gene therapy with nonintegrating
lentiviral vectors. Nat Med. 12:348–353. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Parks RJ, Chen L, Anton M, Sankar U,
Rudnicki MA and Graham FL: A helper-dependent adenovirus vector
system: Removal of helper virus by Cre-mediated excision of the
viral packaging signal. Proc Natl Acad Sci USA. 93:13565–13570.
1996.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Manfredi A, Marrocco E, Puppo A, Cesi G,
Sommella A, Della Corte M, Rossi S, Giunti M, Craft CM, Bacci ML,
et al: Combined rod and cone transduction by adenoassociated virus
2/8. Hum Gene Ther. 24:982–992. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Schön C, Biel M and Michalakis S: Retinal
gene delivery by adeno associated virus (AAV) vectors: Strategies
and applications. Eur J Pharm Biopharm. 95:343–352. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dalkara D, Byrne LC, Klimczak RR, Visel M,
Yin L, Merigan WH, Flannery JG and Schaffer DV: In vivo-directed
evolution of a new adenoassociated virus for therapeutic outer
retinal gene delivery from the vitreous. Sci Transl Med.
5(189ra76)2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Macé E, Caplette R, Marre O, Sengupta A,
Chaffiol A, Barbe P, Desrosiers M, Bamberg E, Sahel JA, Picaud S,
et al: Targeting channelrhodopsin-2 to ON-bipolar cells with
vitreally administered AAV restores ON and OFF visual responses in
blind mice. Mol Ther. 23:7–16. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kiss S: A novel approach to ocular gene
therapy: Evaluation of suprachoroidally administered non-viral DNA
nanoparticles. In: 42nd Annual Meeting of the Macula Society. The
Macula Society, Bonita Spring, FL, 2019.
|
|
8
|
Ramamoorth M and Narvekar A: Non viral
vectors in gene therapy-an overview. J Clin Diagn Res. 9:GE01–GE06.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pitkanen L, Ruponen M, Nieminen J and
Urtti A: Vitreous is a barrier in nonviral gene transfer by
cationic lipids and polymers. Pharm Res. 20:576–583.
2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bloquel C, Bourges JL, Touchard E, Berdugo
M, BenEzra D and Behar-Cohen F: Nonviral ocular gene therapy:
Potential ocular therapeutic avenues. Adv Drug Deliv Rev.
58:1224–1242. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ivanova E, Hwang GS, Pan ZH and Troilo D:
Evaluation of AAV-mediated expression of Chop2-GFP in the marmoset
retina. Invest Ophthalmol Vis Sci. 51:5288–5296. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tshilenge KT, Ameline B, Weber M,
Mendes-Madeira A, Nedellec S, Biget M, Provost N, Libeau L, Blouin
V, Deschamps JY, et al: Vitrectomy before intravitreal injection of
AAV2/2 vector promotes efficient transduction of retinal ganglion
cells in dogs and nonhuman primates. Hum Gene Ther Methods.
27:122–134. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Darrow JJ: Luxturna: FDA documents reveal
the value of a costly gene therapy. Drug Discov Today. 24:949–954.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Davis JL, Gregori NZ, MacLaren RE and Lam
BL: Surgical technique for subretinal gene therapy in humans with
inherited retinal degeneration. Retina. 39 (Suppl 1):S2–S8.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Campochiaro PA, Wykoff CC, Brown DM, Boyer
DS, Barakat M, Taraborelli D and Noronha G: Tanzanite Study Group.
Suprachoroidal triamcinolone acetonide for retinal vein occlusion:
Results of the tanzanite study. Ophthalmol Retina. 2:320–328.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ding K, Shen J, Hafiz Z, Hackett SF, Silva
RLE, Khan M, Lorenc VE, Chen D, Chadha R, Zhang M, et al:
AAV8-vectored suprachoroidal gene transfer produces widespread
ocular transgene expression. J Clin Invest. 129:4901–4911.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
DiCarlo JE, Mahajan VB and Tsang SH: Gene
therapy and genome surgery in the retina. J Clin Invest.
128:2177–2188. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tang PH, Buhusi MC, Ma JX and Crouch RK:
RPE65 is present in human green/red cones and promotes photopigment
regeneration in an in vitro cone cell model. J Neurosci.
31:18618–18626. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Miraldi Utz V, Coussa RG, Antaki F and
Traboulsi EI: Gene therapy for RPE65-related retinal disease.
Ophthalmic Genet. 39:671–677. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gao J, Hussain RM and Weng CY: Voretigene
neparvovec in retinal diseases: A review of the current clinical
evidence. Clin Ophthalmol. 14:3855–3869. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zemba M, Zaharia AC and Dumitrescu OM:
Association of retinitis pigmentosa and advanced keratoconus in
siblings. Rom J Ophthalmol. 64:313–321. 2020.PubMed/NCBI
|
|
22
|
Martinez-Fernandez De La Camara C, Nanda
A, Salvetti AP, Fischer MD and MacLaren RE: Gene therapy for the
treatment of X-linked retinitis pigmentosa. Expert Opin Orphan
Drugs. 6:167–177. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Potop V, Coviltir V, Schmitzer S, Corbu C,
Ionescu IC, Burcel M and Dăscălescu D: The relationship between
corneal hysteresis and retinal ganglion cells-a step forward in
early glaucoma diagnosis. Med Sci Monit. 26(e924672)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cukras C, Wiley HE, Jeffrey BG, Sen HN,
Turriff A, Zeng Y, Vijayasarathy C, Marangoni D, Ziccardi L,
Kjellstrom S, et al: Retinal AAV8-RS1 gene therapy for X-linked
retinoschisis: Initial findings from a phase I/IIa trial by
intravitreal delivery. Mol Ther. 26:2282–2294. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mishra A, Vijayasarathy C, Cukras CA,
Wiley HE, Sen HN, Zeng Y, Wei LL and Sieving PA: Immune function in
X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene
therapy trial. Mol Ther. 29:2030–2040. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Michalakis S, Schön C, Becirovic E and
Biel M: Gene therapy for achromatopsia. J Gene Med.
(19)2017.PubMed/NCBIdoi: 10.1002/jgm.2944.
|
|
27
|
Hassall MM, Barnard AR and MacLaren RE:
Gene therapy for color blindness. Yale J Biol Med. 90:543–551.
2017.PubMed/NCBI
|
|
28
|
Nicoară SD, Șușman S, Tudoran O, Bărbos O,
Cherecheș G, Aștilean S, Potara M and Sorițău O: Novel strategies
for the improvement of stem cells' transplantation in degenerative
retinal diseases. Stem Cells Int. 2016(1236721)2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lam BL, Davis JL, Gregori NZ, MacLaren RE,
Girach A, Verriotto JD, Rodriguez B, Rosa PR, Zhang X and Feuer WJ:
Choroideremia gene therapy phase 2 clinical trial: 24-month
results. Am J Ophthalmol. 197:65–73. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Binley K, Widdowson P, Loader J, Kelleher
M, Iqball S, Ferrige G, de Belin J, Carlucci M, Angell-Manning D,
Hurst F, et al: Transduction of photoreceptors with equine
infectious anemia virus lentiviral vectors: Safety and
biodistribution of StarGen for Stargardt disease. Investig
Ophthalmol Vis Sci. 54:4061–4071. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zallocchi M, Binley K, Lad Y, Ellis S,
Widdowson P, Iqball S, Scripps V, Kelleher M, Loader J, Miskin J,
et al: EIAV-based retinal gene therapy in the shaker1 mouse model
for usher syndrome type 1B: Development of UshStat. PLoS One.
9(e94272)2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Heier JS, Kherani S, Desai S, Dugel P,
Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere
A, et al: Intravitreous injection of AAV2-sFLT01 in patients with
advanced neovascular age-related macular degeneration: A phase 1,
open-label trial. Lancet. 390:50–61. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
REGENXBIO Reports second quarter 2019
financial and operating results and additional positive interim
phase I/IIa trial update for RGX-314 for the treatment of wet AMD.
REGENXBIO, Rockville, MD, 2019. http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-additional-positive-interim-phase-iiia-and/.
Last Updated February 16, 2021.
|
|
34
|
Cashman SM, Ramo K and Kumar-Singh R: A
non membrane-targeted human soluble CD59 attenuates choroidal
neovascularization in a model of age related macular degeneration.
PLoS One. 6(e19078)2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Grishanin R, Vuillemenot B, Sharma P,
Keravala A, Greengard J, Gelfman C, Blumenkrantz M, Lawrence M, Hu
W, Kiss S and Gasmi M: Preclinical evaluation of ADVM-022, a novel
gene therapy approach to treating wet age-related macular
degeneration. Mol Ther. 27:118–129. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Salganik M, Hirsch ML and Samulski RJ:
Adeno-associated virus as a mammalian DNA vector. Microbiol Spectr
3: 10.1128/microbiolspec.MDNA3-0052-2014, 2015.
|
|
37
|
Trapani I, Puppo A and Auricchio A: Vector
platforms for gene therapy of inherited retinopathies. Prog Retin
Eye Res. 43:108–128. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lee JH, Wang JH, Chen J, Li F, Edwards TL,
Hewitt AW and Liu GS: Gene therapy for visual loss: Opportunities
and concerns. Prog Retin Eye Res. 68:31–53. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chung DC, McCague S, Yu ZF, Thill S,
DiStefano-Pappas J, Bennett J, Cross D, Marshall K, Wellman J and
High KA: Novel mobility test to assess functional vision in
patients with inherited retinal dystrophies. Clin Exp Ophthalmol.
46:247–259. 2018.PubMed/NCBI View Article : Google Scholar
|
